Davide Sequino

Davide Sequino

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2022 in Radiology
Verified
Journal Article
Closed access
MBMarialuisa Bocchino
Marialuisa Bocchino
RLroberta lieto
roberta lieto
FRFederica Romano
Federica Romano
Giacomo SicaGiacomo Sica
Giacomo Sica
GBGiorgio Bocchini
Giorgio Bocchini
GRGaetano Rea
Gaetano Rea
In this longitudinal study of patients who had been hospitalized with moderate severity COVID-19 pneumonia, 93% of participants had complete resolution of baseline lung abnormalities on the 12- mon... Background COVID-19 pneumonia may lead to pulmonary fibrosis in the long term. Chest CT is useful to evaluate changes in the lung parenchyma over time. Purpose To illustrate the temporal change of ...

RSRiccardo Scotto
Riccardo Scotto
BPBiagio Pinchera
Biagio Pinchera
FPfrancesco perna
francesco perna
LALidia Atripaldi
Lidia Atripaldi
Agnese GiacconeAgnese Giaccone
Agnese Giaccone
Alessandro  Sanduzzi ZamparelliAlessandro Sanduzzi Zamparelli
Alessandro Sanduzzi Zamparelli
KL-6 is a sialoglycoprotein antigen which proved elevated in the serum of patients with different interstitial lung diseases, especially in those with a poorer outcome. Given that interstitial pneumonia is the most common presentation of SARS-CoV2 infection, we evaluated the prognostic role of KL-6 in patients with COVID-19 pneumonia. Patients with COVID-19 pneumonia were prospectively enrolled. Blood samples were collected at the time of enrolment (TOE) and on day 7 (T1). Serum KL-6 concentrations were measured by chemiluminescence enzyme immunoassay using a KL-6 antibody kit (LUMIPULSE G1200, Fujirebio) and the cut-off value was set at >1000 U/mL. Fifteen out of 34 enrolled patients (44.1%) died. Patients with unfavourable outcome showed significantly lower P/F ratio and higher IL-6 values and plasmatic concentrations of KL-6 at TOE compared with those who survived (median KL-6: 1188 U/mL vs. 260 U/mL, p < 0.001). KL-6 > 1000 U/mL resulted independently associated with death (aOR: 11.29, p < 0.05) with a positive predictive value of 83.3%. Our results suggest that KL-6 is a reliable indicator of pulmonary function and unfavourable outcome in patients with COVID-19 pneumonia. A KL-6 value > 1000 U/mL resulted independently associated with death and showed good accuracy in predicting a poorer outcome. KL-6 may thus represent a quick, inexpensive, and sensitive parameter to stratify the risk of severe respiratory failure and death.

30 December 2022 in Viruses
Verified
Journal Article
Open access
PDF file
GCGaetano Cicchitto
Gaetano Cicchitto
LCLorena Cardillo
Lorena Cardillo
DSDavide Sequino
Davide Sequino
PSPAOLA SABATINI
PAOLA SABATINI
LALuisa Adamo
Luisa Adamo
GFGiovanna Fusco
Giovanna Fusco
Neutralizing monoclonal antibodies (mAbs) for pre- and post-exposure prophylaxis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are largely used to prevent the progression of the disease by blocking viral attachment, host cell entry, and infectivity. Sotrovimab, like other available mAbs, has been developed against the receptor binding Domain of the Spike (S) glycoprotein of the virus. Nevertheless, the latest Omicron variant has shown marked mutations within the S gene, thus opening the question of the efficacy of these neutralizing molecules towards this novel variant. In the present observational study, we describe the effects of Sotrovimab in the treatment of 15 fully vaccinated patients, infected by SARS-CoV-2 Omicron sub-variants, who were selected on the basis of factors widely considered to affect a worse prognosis: immune suppression (n = 12) and/or chronic kidney disease (n = 5) with evidence of interstitial pneumonia in nine patients. The effectiveness of Sotrovimab in the treatment of severe cases of COVID-19 was demonstrated by the regression of symptoms (mean 5.7 days), no need of hospitalisation, improvement of general health conditions and viral clearance within 30 days in all patients. In conclusion, although loss or reduction of mAbs neutralizing activity against the Omicron variant have been described, Sotrovimab has clinically proven to be a safe and useful treatment for patients with high risk of progression to severe COVID-19 infected by Omicron sub-variants.